LLY

886.38

+0.13%↑

UNH

590.76

-0.37%↓

NVO

114.93

-0.16%↓

JNJ

160.38

-0.07%↓

ABBV

194.31

-0.59%↓

LLY

886.38

+0.13%↑

UNH

590.76

-0.37%↓

NVO

114.93

-0.16%↓

JNJ

160.38

-0.07%↓

ABBV

194.31

-0.59%↓

LLY

886.38

+0.13%↑

UNH

590.76

-0.37%↓

NVO

114.93

-0.16%↓

JNJ

160.38

-0.07%↓

ABBV

194.31

-0.59%↓

LLY

886.38

+0.13%↑

UNH

590.76

-0.37%↓

NVO

114.93

-0.16%↓

JNJ

160.38

-0.07%↓

ABBV

194.31

-0.59%↓

LLY

886.38

+0.13%↑

UNH

590.76

-0.37%↓

NVO

114.93

-0.16%↓

JNJ

160.38

-0.07%↓

ABBV

194.31

-0.59%↓

Home・Stock List・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Closed

Sector Healthcare

267.69 -0.7

Buy Sell

Overview

Share price change

24h

Current

Min

265.54

Max

267.9

Key metrics
By Trading Economics
Income	49M -17M
Sales	165M 660M
EPS	0.56
Profit margin	-2.56
Employees	2,100
EBITDA	50M 47M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+14.22 upside

Dividends
By Dow Jones
Next Earnings	31 Oct 2024

Market Stats
By TradingEconomics
Market Cap	-579M 34B
Previous open	268.39
Previous close	267.69

News Sentiment

By Acuity

50%

164 / 366 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

264.84 / 275.39 Support & Resistance

Alnylam Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

12 Sept 2024, 17:01 UTC

Peer Comparison

Price change

Alnylam Pharmaceuticals Inc Forecast

Price Target

By TipRanks

14.22% upside

12 Months Forecast

Average 306.11 USD 14.22%

High 400 USD

Low 233 USD

Based on 22 Wall Street analysts offering 12 month price targets forAlnylam Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

22 ratings

Buy

Hold

Sell

Based on 22 analysts giving stock ratings to Alnylam Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

264.84 / 275.39Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

164 / 366 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational RNAi therapeutics are focused in four Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and CNS/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO (patisiran) is an intravenously administered RNAi therapeutic targeting Transthyretin Amyloidosis (TTR). The GIVLAARI (givosiran) is used to reduce induced liver aminolevulinic acid synthase 1 mRNA, to reduction of toxins associated with attacks and other disease manifestations of Acute Hepatic Porphyria (AHP). The OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of Primary Hyperoxaluria Type 1 (PH1). The Leqvio (inclisiran) is used for the treatment of adults with hypercholesterolemia.